THDB(SH:600867) Xin Lang Cai Jing·2026-02-05 02:07Group 1 - Tsinghua Dongbao's stock price increased by 5.17% to 9.15 CNY per share, with a trading volume of 269 million CNY and a turnover rate of 1.53%, resulting in a total market capitalization of 17.921 billion CNY [1] - Tsinghua Dongbao Pharmaceutical Co., Ltd. was established on December 28, 1992, and went public on August 24, 1994. The company specializes in hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biopharmaceutical products (recombinant human insulin injection) [1] - The main business revenue composition includes: biopharmaceuticals (raw materials and formulations) at 90.29%, medical devices such as injection pens and blood glucose test strips at 6.07%, traditional Chinese medicine and chemical drugs at 2.24%, and others at 1.27% [1] Group 2 - Among Tsinghua Dongbao's top ten circulating shareholders, a fund under Southern Fund holds a significant position. The Southern CSI 500 ETF (510500) reduced its holdings by 352,900 shares in the third quarter, now holding 17.0539 million shares, which accounts for 0.87% of circulating shares [2] - The Southern CSI 500 ETF (510500) was established on February 6, 2013, with a latest scale of 144.69 billion CNY. Year-to-date returns are 11.19%, ranking 482 out of 5566 in its category, while the one-year return is 51.04%, ranking 1152 out of 4285 [2]